Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage.

Seiffge, David J; Kägi, Georg; Michel, Patrik; Fischer, Urs; Béjot, Yannick; Wegener, Susanne; Zedde, Marialuisa; Turc, Guillaume; Cordonnier, Charlotte; Sandor, Peter S; Rodier, Gilles; Zini, Andrea; Cappellari, Manuel; Schädelin, Sabine; Polymeris, Alexandros A; Werring, David; Thilemann, Sebastian; Maestrini, Ilaria; Berge, Eivind; Traenka, Christopher; ... (2018). Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. Annals of neurology, 83(3), pp. 451-459. Wiley-Blackwell 10.1002/ana.25165

Text Seiffge_et_al-2018-Annals_of_Neurology.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (326kB)

OBJECTIVE

Information about Rivaroxaban plasma levels (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban.

METHODS

In a multicenter registry-based study (Novel-Oral-Anticoagulants-In-Stroke-Patients collaboration;NOACISP;ClinicalTrials.gov:NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS-patients had RivLev≤100ng/ml, indicating possible eligibility for thrombolysis and how many ICH-patients had RivLev≥75ng/ml, possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation; regression models) and studied the sensitivity and specificity of INR-thresholds to substitute RivLevs using cross tables and ROC curves.

RESULTS

Among 241 patients (median age 80 years[IQR73-84], median time-from-onset-to-admission 2 hours[IQR1-4.5hours], median RivLev 89ng/ml[31-194]), 190 had AIS and 51 had ICH. RivLev were similar in AIS-patients (82ng/ml[IQR30-202] and ICH-patients (102ng/ml[IQR 51-165]; p=0.24). Trough RivLev(≤137ng/ml) occurred in 126/190 (66.3%) AIS- and 34/51 (66.7%) ICH-patients. Among AIS-patients, 108/190 (56.8%) had RivLev≤100ng/ml. In ICH-patients 33/51(64.7%) had RivLev≥75ng/ml. RivLev were associated with rivaroxaban dosage, inversely with renal function and time-since-last-intake (each p<.05). INR≤1.0 had a specificity of 98.9% and a sensitivity of 25.7% to predict RivLev≤100ng/ml. INR≥1.4 had a sensitivity of 59.3% and specificity of 90.1% to predict RivLev≥75ng/ml.

INTERPRETATION

RivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under Rivaroxaban had RivLev low enough to consider thrombolysis. In ICH-patients, 2/3 had RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR-thresholds perform poor to inform treatment decisions in individual patients. This article is protected by copyright. All rights reserved.

Interest & Impact

Downloads

0 since deposited on 23 Apr 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item